Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot trial of intravenous DP-b99 in first-ever episode of non-obstructive acute high-risk pancreatitis
2013-003652-20Phase 2Terminated
- Sponsor
- D-Pharm
- Start
- Sep 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of DP-b99 in acute pancreatitis (AP), sponsored by D-Pharm. Primary endpoint: Systemic inflammation measured by CRP. Started Sep 2013; status: terminated.
02
Drugs
DP-b99
03
Conditions
acute pancreatitis (AP)
Beyond the preview
Go deeper on 2013-003652-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003652-20.